Medivation Confirms Receipt of Unsolicited Proposal From Sanofi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Medivation (MDVN) Rejects Sanofi's (SNY) Unsolicited Proposal
April 29, 2016 8:46 AM EDTMedivation, Inc. (NASDAQ: MDVN) today announced that its Board of Directors, after consultation with its financial and legal advisors, unanimously determined that the unsolicited proposal from Sanofi (NYSE: SNY) to acquire Medivation for $52.50 per share in cash substantially undervalues Medivation and is not in the best interests of the company and its stockholders.
"Over the past several years, we have established a world class oncology franchise and a unique, diversified and highly-promising late-stage development pipeline," said David Hung, M.D., Founder, President and Chief Executive Officer of... More
Sanofi Has Room for Higher Medivation (MDVN) Bid, Credit Suisse Says; Deal Could Be 7% Accretive in 2020 at $80
April 28, 2016 10:33 AM EDTCredit Suisse analyst Kennen MacKay weighs in on Medivation (NASDAQ: MDVN) after Sanofi launched a $52.50/share hostile bid.
The firm's recent takeover analysis suggested MDVN could be worth $55/share to Sanofi and beleives their conservative estimates indicate Sanofi has more... More
